What to Expect After IVIG Infusion

Most people who receive an IVIG infusion experience mild, short-lived side effects that resolve within a day or two. Headache, chills, low-grade fever, nausea, and fatigue are the most frequently reported reactions, and they tend to be worst during or shortly after the infusion itself. Serious complications are uncommon but real, ranging from aseptic meningitis to kidney injury, and understanding the full spectrum of possibilities helps you recognize when a post-infusion symptom is routine and when it warrants a call to your doctor.

The Most Common Immediate Reactions

The side effects you are most likely to notice happen during the infusion or within the first several hours afterward. Headache tops the list and can range from a dull ache to something intense enough to disrupt your day. Chills, muscle aches, mild fever, and nausea round out the typical picture. These reactions are sometimes grouped together as “flu-like” because they feel a lot like the onset of a cold. They are usually the body’s response to receiving a large load of immunoglobulin protein, and for most people they fade within 24 hours.

Among these, headache deserves special attention because it is both the most common and sometimes the most stubborn. Some people develop headaches that persist for days after each infusion cycle. A case report in a primary-care journal described a patient presenting with severe headache following IVIG, a scenario that clinicians recognize as one of the hallmark adverse effects of the therapy.¹ The intensity varies widely from person to person, and people who are prone to migraines may find that IVIG triggers or worsens them.

How Infusion Speed and Hydration Affect Your Experience

If there is one variable that consistently influences how you feel afterward, it is how fast the infusion runs. A slower drip rate gives your body more time to process the concentrated protein, and research consistently links slower infusion with fewer and milder side effects.² Most infusion centers start at a low rate and gradually ramp up, pausing or dialing back if you begin to feel unwell. If you have had rough reactions in the past, your nurse may keep the rate on the conservative side throughout.

Staying well hydrated before, during, and after the infusion is the other piece of the puzzle. Good hydration helps your kidneys handle the protein load and may reduce the risk of headache, blood-clot complications, and the rare kidney problems described later in this article.³ Drinking plenty of water the day before and the day of infusion is one of the simplest things you can do to improve how you feel afterward.

Premedication and What Actually Helps

Many infusion centers give patients something before the IVIG drip starts in an attempt to head off side effects. The most common premedicating drugs include acetaminophen (Tylenol), diphenhydramine (Benadryl), and sometimes a steroid. A review of strategies for preventing IVIG-induced headaches found that hydration, switching to a different IVIG brand, slowing the infusion rate, and various medications including oral analgesics, triptans, and propranolol all showed some benefit, though the evidence base remains limited to small studies and case reports.⁴

One finding that surprises many patients and some clinicians: premedication with hydrocortisone, a steroid sometimes given before IVIG, may actually make things worse rather than better. A study of pediatric patients receiving IVIG for immune thrombocytopenia found that those who were premedicated with hydrocortisone had roughly double the odds of experiencing an adverse reaction and were more likely to return for medical evaluation afterward. In contrast, patients who received acetaminophen beforehand were less likely to develop problems. Diphenhydramine showed no clear benefit or harm.⁵ If your infusion center routinely gives hydrocortisone before IVIG, it is worth asking whether that practice is truly helping you or whether a simpler approach with acetaminophen and good hydration would be better.

Aseptic Meningitis

This is the complication that sounds the scariest, and for good reason: it involves inflammation of the membranes surrounding your brain. The reassuring part is that aseptic meningitis caused by IVIG is not an infection. There is no bacteria or virus involved. It resolves on its own, typically within a few days, and it does not carry the same dangers as infectious meningitis. Still, the symptoms are unpleasant and alarming. You may develop a severe headache with neck stiffness, sensitivity to light, nausea, and sometimes fever.

The timing is variable. A narrative review of reported cases found that symptoms appeared as early as within 24 hours of the first infusion and as late as 10 days after the last one.⁶ A case report described a patient with dermatomyositis who developed intense head and neck pain with photophobia 24 hours after an IVIG infusion.⁷ If you develop a bad headache with neck stiffness and light sensitivity in the days following your infusion, the emergency department will likely perform a lumbar puncture to rule out infectious meningitis before diagnosing the aseptic variety. The distinction matters because aseptic meningitis from IVIG needs supportive care, not antibiotics.

Delayed Skin Reactions

Some people develop an eczema-like rash that does not appear until a week or more after the infusion, long enough that you might not initially connect it to the IVIG. A case series found that these delayed eczematous skin reactions occurred after the first infusion in about two-thirds of affected patients, with a median onset of 11 days. The most common pattern was pompholyx on the palms and soles, which are small itchy blisters, seen in roughly 63% of patients. Others developed scaly red patches or a more widespread maculopapular rash.⁸

A separate report described four patients who developed a characteristic severe eczematous reaction roughly 10 days after IVIG for a neurological condition. In each case it started with blistering on the palms and then spread to itchy lesions over the whole body. All four were treated with topical or systemic steroids and saw complete resolution within a month.⁹ These reactions are not dangerous in the way that an anaphylactic rash would be, but they are uncomfortable and can look alarming. If you notice a new rash a week or two after IVIG, mention it to your prescribing doctor before your next infusion so they can decide whether to switch products, add preventive treatment, or adjust the regimen.

Hemolytic Anemia and Blood Type

IVIG products are pooled from thousands of blood donors, and those donors collectively carry antibodies against A and B blood-type markers. If your blood type is A, B, or AB (anything other than O), you are receiving antibodies that can attack your own red blood cells. In most cases the effect is mild, showing up only as a slight drop in hemoglobin on lab work. But in some patients receiving high doses, it can tip into clinically significant hemolytic anemia, meaning your body is destroying red blood cells faster than it can replace them.

A study of patients with Guillain-Barré syndrome treated with high-dose IVIG found that all patients with non-O blood types developed clinically significant hemolytic anemia requiring blood transfusion.¹⁰ Research on highly sensitized patients confirmed that non-O blood type and certain liquid IVIG formulations with high levels of anti-A or anti-B antibodies are the key risk factors.¹¹ Signs include unusual fatigue, dark or tea-colored urine, yellowing of the skin or eyes, and rapid heart rate. If you notice any of these in the days after a high-dose infusion, get blood work done promptly. Your doctor may check for hemolysis before and after infusions if you have a non-O blood type and are receiving large doses.

Kidney Concerns and the Sucrose Connection

Acute kidney injury after IVIG is uncommon but has a surprisingly specific culprit: sucrose. Some IVIG products use sucrose as a stabilizing agent, and the kidneys struggle to handle the sugar load when it arrives in large quantities through the bloodstream. The sucrose accumulates in the cells lining the kidney tubules, causing a condition called osmotic nephropathy. A case report documented kidney failure in a patient traced directly to the sucrose in the IVIG formulation.¹²

The association is strong enough to have shifted prescribing practices. Publications have noted that sucrose-stabilized IVIG products account for roughly 88% of reported cases of IVIG-related acute kidney failure, while formulations stabilized with other agents like D-sorbitol carry far lower risk.¹³ If you have any existing kidney issues, your doctor should be choosing a non-sucrose IVIG product and monitoring your kidney function with blood tests around infusion time. Even without pre-existing kidney disease, adequate hydration and a slower infusion rate reduce the strain on your kidneys.

Blood Clots and Viscosity

Flooding the bloodstream with immunoglobulin protein temporarily thickens the blood. This increase in viscosity is measurable and, in some patients, clinically meaningful. A study measuring blood viscosity after high-dose IVIG found that it rose in every patient tested, in some cases exceeding the upper limit of normal and reaching levels that can impair blood flow. The increase happened immediately after the infusion, declined over about a month, and tracked closely with how high serum IgG levels climbed.¹⁴ A separate study confirmed that the concentration of infused IgG strongly correlated with both plasma and whole-blood viscosity, and that the viscosity changes after IVIG could be sufficient to produce heart attack or stroke in patients already at cardiovascular risk.¹⁵

The practical implication is that people with a history of blood clots, heart disease, very high cholesterol, or conditions that already thicken the blood (like certain protein disorders) need to be monitored more carefully during and after IVIG. Staying hydrated, moving around rather than lying still after the infusion, and discussing your cardiovascular risk factors with your doctor before starting therapy are all worth doing. Symptoms to watch for include sudden chest pain, shortness of breath, leg swelling, slurred speech, or sudden weakness on one side of the body. Any of these after an IVIG infusion should be treated as emergencies.

Transfusion-Related Acute Lung Injury

TRALI is one of the rarest but most serious complications of any blood product, including IVIG. It involves sudden respiratory distress, typically within six hours of receiving the product. A case report described a patient who developed TRALI after IVIG infusion, and the authors noted the difficulty of distinguishing TRALI from a different condition called transfusion-associated circulatory overload (TACO), since both can cause breathing problems and fluid in the lungs. In this case, factors like the absence of heart disease, normal cardiac imaging, normal kidney function, and the small volume of fluid administered pointed toward TRALI rather than simple fluid overload.¹⁶ TRALI requires immediate medical attention and is treated with oxygen support and, in severe cases, mechanical ventilation. It is extremely uncommon, but if you develop sudden difficulty breathing during or shortly after an IVIG infusion, the staff administering the treatment need to know immediately.

When the Therapeutic Benefits Kick In

The timeline for feeling the therapeutic effects of IVIG depends heavily on why you are receiving it. For immune thrombocytopenia (ITP), where the goal is to raise dangerously low platelet counts, the response can be rapid. A study of a nanofiltered liquid IVIG product found that most patients with ITP showed an increase in platelet counts after infusion, with roughly 83% responding within one week.¹⁷ For autoimmune neurological conditions like Guillain-Barré syndrome or chronic inflammatory demyelinating polyneuropathy (CIDP), improvement tends to unfold over days to weeks. For primary immunodeficiency, where IVIG is used as long-term replacement therapy rather than a one-time treatment, the benefit is sustained IgG levels that keep you from getting frequent infections. The same pharmacokinetic data showed that infused IgG has a half-life of about 31 days, which is why infusions are typically scheduled every three to four weeks.

The Wear-Off Effect Between Infusions

If you are on a recurring IVIG schedule, you may notice that you start feeling worse in the final days before your next infusion. This is known as the “wear-off” effect, and it is more common than many patients realize. A study tracking patients on three-week and four-week infusion cycles found that about 61% of those on three-week cycles and 43% of those on four-week cycles reported wear-off at least once, as measured by a meaningful drop in overall well-being in the last week of the cycle compared to the second week.¹⁸ Across all cycles, wear-off showed up about 10% of the time.

If you consistently feel run-down, more susceptible to infections, or just generally unwell in the days leading up to your next infusion, bring it up with your immunologist. The solutions include shortening the interval between infusions, adjusting the dose, or switching to subcutaneous immunoglobulin (SCIg), which is given more frequently in smaller amounts and tends to produce steadier IgG levels without the peaks and troughs of monthly IV infusions.

Subcutaneous Immunoglobulin as an Alternative

For people who struggle with IVIG side effects or who find the infusion center visits burdensome, subcutaneous immunoglobulin (SCIg) is an increasingly popular alternative. Instead of receiving a large dose through a vein every few weeks, you self-administer smaller doses into the fatty tissue under the skin, typically weekly or biweekly, often at home. A 12-month observational study of patients with CIDP and multifocal motor neuropathy who switched from IVIG to SCIg found that about 45% experienced some kind of adverse event, but the vast majority were local reactions at the injection site: itching, swelling, hardening, or redness. Only about 6% reported systemic side effects like headache or fatigue.¹⁹ The trade-off is clear: you swap the systemic side effects of IV delivery for localized skin reactions that most patients find tolerable. General guidance on minimizing adverse effects from immunoglobulin therapy notes that switching from IVIG to SCIg is one recognized strategy when intravenous side effects are persistent.²⁰

Live Vaccines and Timing

One practical consequence of IVIG that catches many patients off guard is the impact on vaccinations. Because IVIG floods your system with donated antibodies, those antibodies can neutralize live vaccines before your immune system has a chance to mount its own response. This means live vaccines, including measles-mumps-rubella (MMR) and varicella, need to be delayed after IVIG treatment. Guidelines in Australia and New Zealand recommend postponing live vaccines for 11 months after IVIG treatment for Kawasaki disease, and similar waiting periods apply in other countries and for other IVIG indications.²¹ This is particularly important for children, who are more likely to need catch-up doses of live vaccines. Non-live vaccines (like flu shots or COVID boosters) are generally not affected in the same way, though their effectiveness may be slightly reduced.

If you or your child received IVIG and a vaccination is coming up, make sure the vaccinating provider knows about the IVIG treatment and when it was given. A vaccine administered too soon after IVIG may simply not work, leaving you unprotected without realizing it.

Who Faces Higher Risk

Not everyone starts from the same baseline when it comes to IVIG side effects. Several factors make reactions more likely or more serious:

First-time recipients: Your body has not encountered this protein load before. Many infusion centers run the first infusion especially slowly and with more intensive monitoring for this reason.
Non-O blood type: As described above, people with blood types A, B, or AB face a meaningful risk of hemolytic anemia at high doses.
Pre-existing kidney disease: Particularly if the IVIG product used contains sucrose as a stabilizer.
Cardiovascular risk factors: High blood pressure, prior blood clots, elevated cholesterol, or conditions that already thicken the blood all increase thromboembolic risk.
Older age: The pediatric study on premedication found that older age at administration was independently associated with increased odds of adverse events.⁵ In adults, elderly patients are flagged more broadly as higher risk due to compounding cardiovascular and renal vulnerabilities.
Migraine history: Pre-existing migraine disorder tends to amplify IVIG-induced headaches.

Knowing which category you fall into helps you and your care team decide on appropriate premedication, infusion speed, product choice, and monitoring. If you have multiple risk factors, the first infusion in particular should be treated with extra caution, including slower rates, pre-infusion labs, and close follow-up in the days afterward.